title: [Cisplatin desensitization protocol].
authors.forename: C
authors.initials: C
authors.lastname: Sangrador Pelluz
authors.forename: M
authors.initials: M
authors.lastname: Martínez García
authors.forename: M D
authors.initials: MD
authors.lastname: Pérez-Serrano Lainosa
authors.forename: E
authors.initials: E
authors.lastname: Soler Company
mesh_terms: D000368:Aged; D000707:Anaphylaxis / Q000139:chemically induced* / Q000517:prevention & control; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D054697:Cytostatic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D003888:Desensitization, Immunologic; D004306:Dose-Response Relationship, Immunologic; D006801:Humans; D007262:Infusions, Intravenous / Q000379:methods; D008175:Lung Neoplasms / Q000628:therapy; D008297:Male; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D054697:Cytostatic Agents; D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine